Ultimovacs (ULTI) småprat 1

[Aksjesnila]

@Fornybar

hvor vi på chatten i gjenomsnitt snakker om Ultimovacs 16,5 timer i døgnet. Bli medlem og join oss der, da vel!

Hva jobber dere (ikke) med??

[Fornybar]

Jobb? Min jobb er å spre det gode budskap

fornybar

[h3nk1]

.

[TekBot]

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting

• UV1 immune monitoring data from three Phase I/IIa clinical trials show
  dynamic T cell responses lasting up to 7.5 years
  • Measurable UV1-specific immune response in 91% of patients when combined
    …

Vis børsmeldingen

with checkpoint inhibitor, as compared to 82% and 67% without checkpoint
inhibitor

• Immune responses induced more rapidly when UV1 was combined with a
  checkpoint inhibitor
• Development of UV1-specific immune responses associated with longer survival
  time

Oslo, 10 May 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage
leader in immune stimulatory vaccines for cancer, announced the presentation of
results from long-term follow-up data from three Phase I/IIa clinical. The data
is substantiating the clinical relevancy of the UV1-specific immune response and
the rationale for combining the Company’s lead product, the universal cancer
vaccine UV1, with checkpoint inhibitors.

The data will be presented as a poster at the upcoming Cancer Immunotherapy
(CIMT) annual meeting in Mainz, Germany, 10-12 May 2022. The CIMT poster can be
found on the Company website.

The poster reports on a long-term follow-up study of the use of the UV1 vaccine.
The researchers looked every six months for up to 7.5 years for UV1-specific
immune responses in 51 patients enrolled in three early trials of UV1 in
malignant melanoma, non-small cell lung cancer (NSCLC) and prostate cancer.

For patients with malignant melanoma, where UV1 was combined with the checkpoint
inhibitor ipilimumab, UV1-specific immune responses occurred earlier and more
frequently than in patients with NSCLC or prostate cancer where no checkpoint
inhibitors were involved. 91% of patients with malignant melanoma showed a
detectable immune response within three months.

The high rate and rapid induction of immune responses provide support for
synergy between UV1 vaccination and checkpoint inhibition. The data further
demonstrate that UV1 vaccination leads to induction of memory T cells with an
inflammatory cytokine profile. These cytokines produced by the UV1-specific T
cells, including IFN-gamma and TNF-alpha, are considered appropriate in terms of
supporting anti-tumor activity. Immune response induction associated with longer
survival time, with a median overall survival in immune responders of 54.8
months, compared to 23.4 months in non-immune responders.

“These data - from what we believe to be the longest immune monitoring study of
a therapeutic cancer vaccine - are highly relevant to Ultimovacs’ ongoing Phase
II programs in which UV1 is combined with various checkpoint inhibitors, as well
as to potential future clinical studies. The data shows that the patients’ UV1-
specific immune responses may be embedded in immune memory, providing the
potential for dynamic long-term defenses against cancer” said Carlos de Sousa,
Chief Executive Officer of Ultimovacs.

                                ==ENDS==

About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to
treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine
candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in
all stages of tumor growth. By directing the immune system to hTERT antigens,
UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade
and increase anti-tumor responses. With a broad Phase II program in five cancer
indications enrolling more than 650 patients, Ultimovacs aims to clinically
demonstrate UV1’s impact in multiple cancer types, in combination with other
immunotherapies, for patients with unmet needs. Ultimovacs’ second technology
approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform,
combines tumor-specific peptides and adjuvant in the same molecule and entered
Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 90686815

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on 10 May, 2022 at 08:00 CET.

Kilde

[polygon]

“The data shows that the patients’ UV1-specific immune responses may be embedded in immune memory, providing the potential for dynamic long-term defenses against cancer”

Den setningen kan man med hell lese og smake på et par ganger.

Eller som det står i posteren beregnet for et annet publikum: “Persisting IRs were detected in several patients, demonstrable up to 7.5 years after the first vaccination, often with proliferative responses exceeding those observed during the immunization period.”

[h3nk1]

@TekBot

“These data - from what we believe to be the longest immune monitoring study of a therapeutic cancer vaccine - are highly relevant to Ultimovacs’ ongoing Phase II programs in which UV1 is combined with various checkpoint inhibitors, as well as to potential future clinical studies. The data shows that the patients’ UV1-specific immune responses may be embedded in immune memory, providing thepotential for dynamic long-term defenses against cancer” said Carlos de Sousa, Chief Executive Officer of Ultimovacs.

Rene ord for penga

N = 51.

[Fornybar]

Ultimovacs leverer, leverer OG leverer, @vegar_beider

Rasjonalet for effekt av UV1 + ICI er så vanntett at selv ikke kanonene på Oscarsborg kunne senket det om det kom seilende inn Oslofjorden.

[polygon]

Men likevel får vi enda en dag med: Vaksine som meget sannsynlig både kurerer og hindrer kreft? Nei takk - det blir jo inflasjon!

[Fornybar]

Min store oppgave her i livet er å gjøre mitt aller beste for å finne informasjon som motbeviser ideen jeg har om at UV1 vil gi effekt sammen med sjekkpunkthemmere. Alt jeg finner som publiseres rundt kreftvaksiner bare bygger på rasjonalet.

[h3nk1]

Figure 4: Across all trials, immune responders had prolonged survival compared to non-immune responders (mOS, 54.8 months vs. 23.4 months, log-rank p-value 0.05)

P-verdi 0,05

[rosasky]

Dette innlegget ble rapportert og er midlertidig skjult.

[polygon]

Ja, best å vente til bioteks har inntekter før man kjøper seg inn.

[h3nk1]

Anbefaler deg å kjøpe etter avtalen for UV1 er på plass. Så slipper du klinisk risiko. Kursmål 21.000,- eller var det 36.000?

[Fornybar]

@rosasky

Edit: Skal vurdere inngang på 63 om resultatene fortsetter å virke lovende

Du er en sjarmerende type (troll) men du har et poeng i at hva som helst kan skje siden finansmarkedene er i krise.

[rosasky]

Mangler ikke på luftige kursmål hvertfall.

En avtale om UV1 som sender kursen til 36.000 hadde vært kult.
Kanskje det kommer til 17. mai så blir det ei ekstra med sjampis?

[erpe80]

Köper på 30kr med kursmål 100 000;- Köp rek

[h3nk1]

Ny Form Troll magnet - tvillinger (Troll nr. 2003)

[Fornybar]

Dagens fun fact

[Fartin]

@h3nk1

Across all trials , immune responders had prolonged survival compared to non-immune responders (mOS, 54.8 months vs. 23.4 months, log-rank p-value 0.05

Immune responders har svært lang overlevelse sammenlignet med noen immun responders.

Hvor mange av pasientene i f ase 1/2 som fikk uv1 hadde immun respons? Denne prosenten vil cel sannsynligvis være rimelig lik i initium etc.

[polygon]

Ingen som svarte deg…

På posteren står det: The IR rates were 91%, 67%, and 82% for the melanoma, NSCLC, and prostate cancer trials, respectively.

På US-pembro studien, så har vi vel ikke dette tallet, tror jeg. Men man kan sikkert regne med at det er rundt 90% et sted. Jeg er ikke sikker på om de måler dette i INITIUM i det hele tatt. Det er jo klinisk effekt som er målet (og det som primært måles), og immunrespons er jo bare et signal om dette.